The HIV lipodystrophy or fat redistribution syndrome is a heterogeneous condition characterized by particular body-shape changes, often accompanied by dyslipidaemia and disorders of glucose homeostasis [1, 2] . Although this syndrome has been associated with an increased cardiovascular risk [2] , data supporting this link are scarce and contradictory [3] [4] [5] [6] [7] [8] [9] [10] . Carotid intimamedia thickness was found to be increased in HIVinfected patients with lipodystrophy in some studies [3] , whereas others did not confirm these results [4, 5] . Likewise, some biomarkers associated with increased cardiovascular risk have been explored in patients with lipodystrophy, also with discordant results [6] [7] [8] [9] [10] .
Besides the uncertainty about its role in cardiovascular disease development, it is still not known whether the fat distribution change alone, in the absence of the accompanying metabolic abnormalities, contributes to augment the risk. It is well known that the metabolic syndrome, which comprises abdominal fat accumulation, dyslipidaemia and insulin resistance, is associated with increased total and cardiovascular disease mortality in the general population [11, 12] Introduction and glucose disorders directly influence atherogenesis, metabolic and fat redistribution changes have distinct pathological pathways and might occur separately in HIV-infected patients [13, 14] . As it is not infrequent for patients with lipodystrophy to lack overt glucose or lipid disorders, it should be of interest to know if such patients also carry an increased cardiovascular risk and the pathogenic mechanisms implicated. Endothelial dysfunction is considered an early event in the development of atherosclerosis [15, 16] . Flowmediated dilatation (FMD) of the brachial artery currently constitutes the most reproducible non-invasive method to evaluate endothelial dysfunction [17] . To date, no published data exist about FMD measurements in HIV-infected patients with lipodystrophy compared with those without lipodystrophy.
In order to clarify the association of fat redistribution with increased cardiovascular disease risk, we evaluated FMD in HIV-infected patients with and without lipodystrophy. Specifically, we aimed to determine whether patients with lipodystrophy have endothelial dysfunction more frequently, whether there are differences between the different patterns of fat redistribution and the contribution of lipodystrophy to endothelial dysfunction after adjusting for traditional cardiovascular risk factors. We also explored the association of lipodystrophy and endothelial dysfunction with several proatherosclerotic biomarkers released by adipose tissue or related to vascular function.
Methods

Study design and population
The study was conducted at the HIV outpatient's clinic of the University Hospital of Elche, Elche, Spain. Consecutive healthy HIV-infected adults with lipodystrophy (see below) visiting from January 2008 to June 2008 were invited to participate if they had been receiving antiretroviral therapy (ART) for at least 2 years and had been on a stable drug regimen for at least 6 months. Lipodystrophy was defined as the presence of body-fat changes that could be clearly recognised by both the patient and the doctor. Body-fat change patterns were classified into three categories: isolated lipoatrophy (defined by hollow cheeks, prominent superficial veins in the arms or legs or flattening of the buttocks); isolated lipohypertrophy (defined by increased abdominal girth, increased chest or breast fat or dorsocervical fat pad); and mixed lipodystrophy, when lipoatrophy and lipohypertrophy patterns coexisted. Each body-fat change was scored from 0 (no lipodystrophy) to grade 3 (most severe lipodystrophy). Grade 2 and 3 were considered as severe lipodystrophy. For each patient with lipodystrophy, we randomly selected a subject without lipodystrophy matched by age (±5 years) and sex from among those cared for in the clinic during the study period who met the same inclusion criteria as did patients with lipodystrophy. To avoid patient misclassification, all patients were evaluated by three independent investigators and were only considered eligible if total agreement existed regarding the presence and severity of lipodystrophy between the three investigators. Patients were excluded if no agreement concerning lipodystrophy was achieved by the investigators, if they had an active or recent opportunistic infection or other acute inflammatory condition, or were actively using intravenous drugs or cocaine. The investigation was approved by the Ethics Committee for Clinical Research and the patients' informed consent was obtained.
Clinical and laboratory measurements
Details were taken of age, HIV transmission category, stage of HIV infection according to Centers of Disease Control and Prevention (CDC) criteria, duration of ART, current antiretroviral medication, coinfection with hepatitis B or C virus, cardiovascular risk factors and pharmacological treatment of dyslipidaemia, diabetes or hypertension. Patients were classified as having dyslipidaemia, diabetes or hypertension if they had a previous diagnosis or if they were on pharmacological therapy for those disorders. Homeostatic assessment of insulin resistance (HOMA-IR) index was calculated as the product of the fasting plasma insulin level (mU/ml) and the fasting plasma glucose level (mmol/l), divided by 22.5. The 10-year risk of developing myocardial infarction or coronary death was calculated for each patient with the Framingham equation.
Blood samples were collected after an 8 h overnight fast for measurement of glycaemia, total cholesterol, high-density lipoprotein (HDL) cholesterol, direct lowdensity lipoprotein (LDL) cholesterol, triglycerides, creatinine, insulinaemia, CD4 + T-cell count and HIV plasma viral load. An additional sample was processed by centrifugation. Plasma aliquots obtained were stored at -80ºC. All frozen samples were subsequently defrosted and plasma levels of several biomarkers potentially associated with lipodystrophy, endothelial dysfunction or cardiovascular disease risk were simultaneously measured. More precisely, we determined levels of soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular cell adhesion molecule 1 (sVCAM-1) and soluble E-selectin (sE-selectin) as endothelial function markers; the adipokines adiponectin and leptin; high sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6) and tumour necrosis factor α (TNF-α) as inflammatory biomarkers; and plasminogen activator inhibitor 1 (PAI-1) as a procoagulative marker.
Plasma concentrations of IL-6, TNF-α, sVCAM-1, sICAM-1, sE-selectin and PAI-1 were measured using commercially available ELISA kits (Quantikine; R&D Systems Europe Ltd, Abingdon, UK). Plasma levels of hsCRP were measured using the IMMULITE 2000 Analyzer (Siemens, Los Angeles, CA, USA), as previously described [18] . Plasma levels of adiponectin and leptin were measured using a commercially available enzyme immunoassay (EIA) kit (Cayman Chemical, Ann Arbor, MI, USA).
Evaluation of endothelial function
Endothelial function was evaluated measuring FMD. Patients were required to be fasting and not to use any tobacco-containing products for 8 h before the study. Patients were placed in a supine position and a blood pressure cuff was placed on the widest part of the proximal right forearm, approximately 1 cm distal to the antecubital fossa. Using a high-resolution (≥7 MHz) linear array vascular ultrasound transducer (Toshiba Nemio; Toshiba Medical Systems Europe; Zoetermeer, The Netherlands), the brachial artery was located above the elbow and scanned in longitudinal sections. Baseline vessel diameter was determined with the mean of three measures. The forearm cuff was inflated to 240 mm Hg for 5 min to induce reactive hyperaemia. FMD of the brachial artery was measured 1 min after cuff deflation as described above. After a 10 min rest period, nitroglycerine-mediated vasodilatation (NTGMD), a marker of endothelium independent vasodilatation, was measured 4 min after the administration of sublingual nitroglycerine (400 µg). FMD was calculated as the ratio of the brachial artery diameter after reactive hyperaemia to baseline diameter and was expressed as a percentage of change. NTGMD was calculated in an analogous fashion. Measurements were performed by a single sonographer blinded to patient information and treatment. Reproducibility was assessed in 10 healthy patients (8 men, age 44 ±8.5 years) who were examined by the same sonographer twice, at an interval of 2 h. The median (interquartile range, IQR) intra-observer intersession percentage of variation for brachial artery diameter was 2.38% (0-5.71); this was similar to the value found in previous studies [19] .
Statistical analysis
Descriptive analysis of the baseline characteristics of patients with and without lipodystrophy was performed using frequency distributions for categorical variables and median and IQR for continuous variables, respectively. Differences in demographic and clinical characteristics between patients with and without lipodystrophy were assessed using the χ 2 or Fisher's exact test for categorical variables and Mann-Whitney test for continuous variables. Mann-Whitney or Kruskal-Wallis tests were used to examine the strength of association between FMD and plasma biomarkers with categorical variables. The bivariate Spearman correlation test was used to examine the strength of association between FMD and other continuous variables.
A logistic regression analysis was performed to assess the contribution of lipodystrophy to endothelial dysfunction. The lowest quartile of FMD was chosen as dependent variable. All variables thought to influence FMD levels, including traditional cardiovascular risk factors (age, sex, hypertension, dyslipidaemia, diabetes and 10-year coronary heart disease risk according to the Framingham score), pro-atherosclerotic biomarkers (adiponectin, leptin, hsCRP, IL-6, TNF-α, sVCAM-1, sICAM-1, sE-selectin and PAI-1) and factors associated with HIV infection (CD4 + T-cell count, HIV viral load, protease inhibitor [PI]-based regimens, nonnucleoside reverse transcriptase inhibitor [NNRTI]-based regimens, time of exposure to ART, male-to-male sex transmission category and category C of the CDC classification system) were included. All P-values were two-tailed. Data were analysed using the SPSS software package version 12.0 (SPSS Inc., Chicago, IL, USA).
Results
Population characteristics
During the study period, 108 of the 479 patients seen in the clinic met the inclusion criteria for lipodystrophy. Of these 108 patients, 83 met all the eligibility criteria, but 12 declined to participate and 16 additional patients had exclusion criteria (no agreement about lipodystrophy in 12 patients, active intravenous drug use in 2 patients, voluntary ART interruption in 1 patient and bacterial pneumonia in 1 patient). A total of 55 patients with lipodystrophy were finally included. Of the 361 patients without lipodystrophy cared for in the clinic during the same period, 252 patients met the inclusion criteria and 203 were fully eligible (9 patients were excluded because there was no agreement about lipodystrophy existence, 27 declined to participate, 9 had an acute inflammatory condition and 4 were active intravenous drug users). Among these 203 patients, we randomly selected 55 matched by age (±5 years) and sex with subjects with lipodystrophy. Demographic characteristics of the patients excluded from the study were not significantly different from the included patients.
Of the 55 patients with lipodystrophy, 30 (54.5%) had isolated lipoatrophy, 5 (9.1%) isolated lipohypertrophy and 20 (36.4%) patients had mixed lipodystrophy; 31 (55.4%) patients had severe lipodystrophy.
Baseline characteristics of patients with and without lipodystrophy are shown in Table 1 . Patients with lipodystrophy were more likely to be males that had sex with males and to be included in the category C of the CDC classification system, they had a higher frequency of dyslipidaemia, higher insulinaemia, HOMA index and waist-to-hip ratio, longer total exposure to ART and were more likely to be currently exposed to NNRTIs and less likely to be currently on PIs than patients without lipodystrophy (P<0.05 for all). These patients also tended to have higher triglyceride levels (P=0.06) and higher 10-year coronary heart disease risk (P=0.08).
Plasma biomarkers
Patients with lipodystrophy had significantly higher levels of IL-6 (P=0.003) and PAI-1 (P=0.003), and lower levels of adiponectin (P=0.001) than patients without lipodystrophy. Severe lipodystrophy was associated with lower concentrations of adiponectin (P=0.013) and higher concentrations of sVCAM-1 (P=0.035), IL-6 (P=0.034) and PAI-1 (P=0.005) compared with no lipodystrophy (Table 2) .
Levels of the biomarkers according to category of lipodystrophy are shown in Figure 1 + T-cell count or viral load. When the relationship of FMD and the pro-atherogenic biomarkers was evaluated, we found a negative correlation between FMD and IL-6 (Spearman's rho =-0.26; P=0.007), and a trend towards a positive correlation of FMD with adiponectin (Spearman's rho =0.15; P=0.11). No correlation was found between FMD and PAI-1, TNF-α, sVCAM-1, sICAM-1, sE-selectin or hsCRP. Patients diagnosed with or receiving therapy for dyslipidaemia had a significantly lower percentage of FMD (P=0.01), which also tended to be lower in patients with diabetes (P=0.06) or hypertension (P=0.07) and was significantly higher in current smokers (P=0.02). Antiretroviral regimen composition did not influence FMD values. There were no significant differences in endothelial function between patients on a PI-or an NNRTI-based antiretroviral regimen. Likewise, FMD did not differ according to nucleoside reverse transcriptase inhibitor (NRTI) regimen composition, including the presence or absence of thymidine analogues. To define endothelial dysfunction, we chose the lowest quartile of FMD (≤2%). Patients with lipodystrophy had a higher frequency of FMD values ≤2% (35.5% versus 12.1%, respectively; P=0.003) and the same was true for patients with isolated lipoatrophy compared with all the other patients (43.3% versus 17.5%; P=0.01). According to this definition, factors associated with endothelial dysfunction were lipid-lowering therapy (P=0.014), diabetes (P=0.024), a 10-year Framingham score >10 (P=0.005) and an antiretroviral regimen based on NNRTIs (P=0.039). By contrast, a PI-based antiretroviral regimen (P=0.01) and smoking (P=0.04) were protective factors against the lowest quartile. When smoking exposure was quantified in pack years, and current and former smokers were included, no relationship was observed with endothelial dysfunction ( A multivariate regression model was constructed to assess the relationship of endothelial dysfunction with lipodystrophy and with all the variables described above along with non-significant variables related to cardiovascular risk factors and HIV infection, such as sex, age, hypertension, waist-to-hip ratio, all proatherosclerotic plasma biomarkers, category C of the CDC classification system, male-to-male sex transmission category and time of exposure to ART. Using the lowest quartile of FMD as the dependent variable, the only independent predictor of endothelial dysfunction in the model was lipodystrophy (odds ratio [OR] 4.19, 95% confidence interval [CI] 1.38-12.79; P=0.012). When lipodystrophy was excluded from the model, IL-6 (OR 1.17, 95% CI 1.01-1.35; P=0.04) and diabetes (OR 3.93, 95% CI 1.08-14.30; P=0.038) were the variables associated with the lowest quartile of FMD. When FMD was analysed as a continuous variable in a multivariate linear regression model adjusted by all the above cardiovascular risk factors, both lipodystrophy and IL-6, along with a 10-year Framingham score >10%, were the only significant variables associated with FMD. In this model, IL-6 was the best predictor of FMD.
Discussion
We found that FMD is decreased in patients with lipodystrophy. Although some studies have raised doubts about its association with cardiovascular risk in the general population and in HIV-infected patients [20, 21] , impaired brachial FMD has been shown to be related to the prevalence and extent of coronary atherosclerosis [22] and to predict future cardiovascular events [23] . According to our results, patients with lipodystrophy would have a higher risk of coronary heart disease development. This increased risk was independent of the presence of overt hyperlipidaemia, diabetes and the other traditional cardiovascular risk factors, suggesting that additional factors might be implicated in the detrimental cardiovascular effects of lipodystrophy.
Patients with lipodystrophy showed proatherosclerotic concentrations of several adipose tissue and endothelial function related biomarkers, including higher plasma levels of IL-6, PAI-1 and sVCAM-1, and lower levels of adiponectin. IL-6 is an adipocytokine with proinflammatory actions that is produced in many cell types, including adipocytes [12] ; it is thought to play a major role in the pathogenesis of atherosclerosis [24, 25] . IL-6 has been found to induce endothelial dysfunction [24] . In agreement with this, an inverse correlation existed between IL-6 levels and FMD values in our patients. Although no pro-atherogenic biomarker was independently associated with endothelial dysfunction in a logistic regression model when lipodystrophy was included as a predictor variable, lipodystrophy might represent a confluence of several disturbed pathophysiological mechanisms with a better prediction capacity than any of the biomarkers separately. When lipodystrophy was excluded from the model, IL-6 turned out to be an independent predictor of endothelial dysfunction. Among its actions, IL-6 also attenuates insulin sensitivity [26] and a reciprocal relationship has been described between insulin resistance and endothelial dysfunction [27, 28] . Our HIV-infected patients with lipodystrophy had higher plasma levels of insulin and HOMA-IR index than patients without lipodystrophy. Finally, IL-6 concentrations are inversely related to the levels of adiponectin, suggesting that this cytokine is one of the regulators of adiponectin production [29] . Patients with lipodystrophy in our study had lower concentrations of adiponectin, an anti-atherogenic adipokine with antidiabetic and anti-inflammatory properties [30, 31] . Adiponectin exerts anti-inflammatory actions by suppressing the production of some cytokines, like IL-6 or TNF-α, and by decreasing expression of adhesion molecules in endothelial cells in response to inflammatory stimuli [29, 32] . Accordingly, levels of sVCAM-1 were higher in our patients with body-fat redistribution.
We did not find a correlation between the levels of vascular adhesion molecules and FMD. The lack of such a correlation had been described previously with several of the adhesion molecules [33, 34] . One of the proposed explanations might be that adhesion molecules such as ICAM-1 and VCAM-1 are expressed on numerous cells apart from the endothelium, like inflammatory leucocytes or smooth muscle cells, and might therefore be general markers of universal low-grade systemic inflammation rather than specifically of vascular inflammation [35] .
Patients with lipodystrophy had increased concentrations of PAI-1, a potent inhibitor of fibrinolysis, which has been shown to be an independent risk factor for cardiovascular disease development [9, 36] . Plasma PAI-1 is produced by adipocytes, and hence is included among the adipokines [37] , but it is also synthesized by hepatocytes, endothelial cells and platelets [9, 36] . Augmented PAI-1 concentration had been previously described in HIV-infected patients with lipodystrophy [9, 38] , but the mechanisms implicated are currently under investigation.
Lipodystrophy categories showed differences in the endothelium-dependent vasodilator response. The lowest FMD was found in patients with isolated lipoatrophy. Lipoatrophy was also the only lipodystrophy pattern in which the relationship with FMD remained significant after adjusting for the potential confounders associated with lipodystrophy (data not shown). Although some patients exhibit both lipoatrophy and lipohypertrophy, the two entities have different etiologies and, in general, occur independently [39] [40] [41] . Our findings suggest that endothelial dysfunction might contribute to increased cardiovascular risk in patients with lipodystrophy and that it occurs preferentially in patients with lipoatrophy. Although the mechanisms by which lipoatrophy might impair endothelial function remain unclear, adipokines could be involved. In our study, lipoatrophy and mixed lipodystrophy were the categories associated with the lowest levels of the antiatherogenic adipokine adiponectin.
Patients not exhibiting lipodystrophy had a lower frequency of endothelial dysfunction than patients with lipodystrophy; however, median FMD values in the former patients were somewhat lower than those expected for age-matched, HIV-negative patients [42, 43] . Such results are in agreement with previous studies of endothelial function in HIV-infected patients [44] [45] [46] and support the proposal that several factors might be implicated in the vascular dysfunction of such patients, including the direct effects of HIV and ART. Antiretroviral-experienced patients and those receiving PIs have been found to have endothelial dysfunction in cross-sectional studies [47, 48] . Both circumstances have also been linked with lipodystrophy. Interestingly, current use of abacavir has recently been independently associated with impaired endothelial function [49] . Although patients on abacavir in our study had lower FMD values, the difference with patients receiving other NRTIs was not statistically significant and there was no difference in FMD among patients on abacavir with or without lipodystrophy (data not shown). The improvement of endothelial function in ART-naive patients starting therapy [50] suggests that factors inherent to HIV infection, among which those predisposing some patients to develop lipodystrophy could be included, might also play a role in the increased cardiovascular risk of HIV-infected patients.
The cross-sectional design of the study must be taken into account when interpreting some of the results obtained. For instance, the association on univariate analysis of NNRTIs and PIs with body-fat redistribution or with endothelial dysfunction might reflect clinicians prescribing practices of ART in patients with lipodystrophy, rather than a risk factor for lipodystrophy or for impaired FMD. The inverse relationship between smoking status and FMD in univariate analysis was also an unexpected finding; however, this relationship did not remain significant when smoking habit was quantified in pack years and there was even a trend towards a higher cigarette exposure among individuals with endothelial dysfunction. Interestingly, among non-smokers there was a significantly higher frequency of hypertensive and diabetic patients and those over 50 years old (data not shown), which might have contributed to the former results; the frequency of pre-existing cardiovascular disease was the same among smokers and non-smokers (P=1.0; data not shown). The definition of lipodystrophy based on the subjective criteria of the patients and doctors should also be mentioned as a limitation; however, there is currently a lack of a standardized definition of lipodystrophy and total agreement by three independent investigators was required regarding the presence and severity of lipodystrophy. Another potential limitation is the small number of patients included, which might have precluded us from finding an association between endothelial function and several of the biomarkers explored. Nevertheless, the number of patients included did allow us to detect differences between patients with and without lipodystrophy and between the different patterns of lipodystrophy.
In conclusion, in HIV-infected patients, lipodystrophy (and mainly lipoatrophy) is associated with endothelial dysfunction. This association is independent of traditional cardiovascular risk factors. IL-6 might be one of the alternative factors contributing to this relationship, as it was raised in patients with lipodystrophy and was also a predictor of endothelial dysfunction. Plasma levels of other biomarkers of inflammation, insulin resistance and procoagulation were also elevated in patients with lipodystrophy. These findings support a link between lipodystrophy and increased cardiovascular disease risk and could help us to gain a deeper insight into the pathogenic mechanisms implicated.
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